Delivery Order SPE2DB22D3016-SPE2DB25FBJL9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Rexulti 2 mg tablets (30-count) valued at $34,056.64. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. The pharmaceutical product will be performed at the...
- The Defense Logistics Agency awarded a delivery order valued at $10,096.14 to AmerisourceBergen Drug Corp for the supply of Rexulti 3 mg tablets (30-count packages) on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) under a firm fixed-price arrangement. The contract, valued at $5,048.63, was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor...
- The Defense Logistics Agency awarded a delivery order valued at $26,659.20 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $7,915.80 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Rexulti 1 mg tablets (30-count). This firm fixed-price, non-set-aside contract is scheduled for completion by July 28, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $6.8K delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Rexulti 0.5 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is classified as a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The pharmaceutical will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $3,499.29 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units). This competitive award, issued on June 18, 2025, with an ultimate completion date of June 20, 2025, carries a firm fixed price and no set-aside designation. The contract represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global...
- The Defense Logistics Agency awarded a $2,927.91 delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price contract, issued without a set-aside designation, represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreements. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,809.99 on September 16, 2025, for the supply of Rexulti 1 mg tablets (30-count package). This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by September 17, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the pharmaceutical distributor maintains its corporate headquarters. This delivery order...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBJL9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,259.14 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packaging). This firm fixed-price delivery order, issued on September 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 17, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. As the prime contractor on this delivery order, the company supplies a comprehensive range of pharmaceutical products to the Defense Health Agency and other government healthcare entities. The DLA Pharmaceutical Prime Vendor Global Program provides a flexible contracting mechanism that enables efficient delivery of essential medications, including specialty pharmaceuticals like Rexulti, to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 9/16/25 |